Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patie
Coronary Intervention (COMPASS-PCI)

Circulation

141, 1141-1151

DOI: 10.1161/circulationaha.119.044598

Citation Report

#	Article	IF	Citations
1	Adverse Events Beyond 1 Year After Percutaneous Coronary Intervention. Current Opinion in Cardiology, 2020, 35, 687.	2.2	12
2	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents. Circulation, 2020, 142, 1425-1436.	24.6	175
3	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. Circulation, 2020, 142, 1579-1590.	24.6	55
4	Unravelling the Puzzle of Antithrombotic Therapies for Complex Percutaneous Coronary Intervention. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 352-359.	5.0	11
5	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
6	Review on Characteristics and Analytical Methods of Rivaroxaban. Critical Reviews in Analytical Chemistry, 2022, 52, 865-877.	7.9	24
7	Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease. Circulation, 2020, 141, 1855-1858.	24.6	2
8	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	2.4	5
9	Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. Thrombosis and Haemostasis, 2021, 121, 854-866.	4.6	13
10	The Year in Cardiovascular Medicine 2020: Interventional Cardiology. European Heart Journal, 2021, 42, 985-1003.	14.7	23
11	Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e019184.	5.8	16
12	Dual Therapy With an Oral Non-Vitamin K Antagonist and a P2Y12 Inhibitor vs Triple Therapy With Aspirin, a P2Y12 Inhibitor and a Vitamin K Antagonist for the Treatment of Diabetes Mellitus Patients With Co-Existing Atrial Fibrillation Following Percutaneous Coronary Intervention: A Meta-Analysis. Medicine (United States), 2021, 100, e25546.	2.1	2
13	Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania. American Journal of Therapeutics, 2021, 28, e271.	1.1	2
14	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. Journal of the American College of Cardiology, 2021, 78, 859-866.	12.0	55
15	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	5.8	15
16	Prolonged Antithrombotic Therapy in Patients After Acute Coronary Syndrome: A Critical Appraisal of Current European Society of Cardiology Guidelines. Cardiology Journal, 2020, 27, 661-676.	1.7	11
17	Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment. US Cardiology Review, 2021, 15, e17.	2.3	0
18	Residual Risk Reduction Opportunities in Patients With Chronic Coronary Syndrome. Role of Dual Pathway Inhibition. Expert Review of Clinical Pharmacology, 2020, 13, 695-706.	3.6	6

#	Article	IF	Citations
19	Independent Impact of Peripheral Artery Disease on Percutaneous Coronary Intervention. Journal of the American Heart Association, 2020, 9, e017655.	5.8	15
20	Optimum Treatment Strategy in Chronic Coronary Syndromes: The New Trials vs the Current Guidelines. Rational Pharmacotherapy in Cardiology, 2021, 17, 761-770.	0.6	0
21	In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life, 2022, 12, 393.	4.3	68
22	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. Current Cardiology Reports, 2022, 24, 277-293.	4.5	2
23	Nastal Čas nahradit monoterapii kyselinou acetylsalicylovou v sekundární prevenci účinnější léčbou?. Cor Et Vasa, 2022, 64, 305-309.	0.3	0
24	Percutaneous Coronary Intervention With Peripheral Artery Disease in the Contemporary Era: Still Life or Limb?. Atherosclerosis, 2022, 355, 45-47.	7.0	1
25	Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis. Circulation: Cardiovascular Interventions, 2022, 15, e011990.	6.2	35
26	Recent Advances in Antiplatelet Therapy in Complex Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2022, 11, 419-428.	1.1	5
27	Comparative Efficacy and Safety of Antiplatelet or Anticoagulant Therapy in Patients With Chronic Coronary Syndromes After Percutaneous Coronary Intervention: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2022, 13, 992376.	5.3	8
28	Efficacy and Safety Outcomes of Long-Term Anti-Thrombotic Treatment of Chronic Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2023, 9, 1016390.	3.2	0
29	Сахарный диабет 2 типа и микрососудистые осложнения у больных стабильной ишемической болезнью сердца: распространенность, прогноз и выбор антитромботической терапии. Ûžno-Rossijskij žurnal Terapevtičeskoj Praktiki, 2022, 3, 7-24.	0.3	4
30	Optimal Antiplatelet Therapy Revisited: When Is a Single Better Than a Double?. Journal of the American College of Cardiology, 2023, 81, 553-556.	12.0	3
31	Low Dose Rivaroxaban for the Management of Atherosclerotic Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2023, 56, 91-102.	2.2	9
32	Low-Dose Rivaroxaban: Can Cardiovascular Events Be Reduced?. European Heart Journal Supplements, 2023, 25, C20-C26.	2.9	4
33	New-Onset Stroke on the Risk of Hip Fracture: The Kailuan Cohort Study in China. BMC Public Health, 2023, 23, 1-10.	4.8	7
34	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2023, 82, 833-955.	12.0	620
35	Clinical Benefits of Oral Anticoagulants in Atrial Fibrillation Patients With Dementia: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2023, 10, 1265331.	3.2	8
36	Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2024, 40, 160-181.	3.8	48

#	Article	IF	Citations
37	Clopidogrel Monotherapy in Older Stable Ischemic Heart Disease Patients Receiving Percutaneous Coronary Intervention: A Paradigm Shift?. Canadian Journal of Cardiology, 2024, 40, 53-55.	3.8	2
38	Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives. Cardiology, 2024, 149, 502-512.	1.7	5
39	Chinese Expert Consensus on Anti-Thrombotic Therapy for Pan-Vascular Diseases (2023 Edition). Cardiology Plus, 2024, 9, 49.	1.7	10
40	Current Management of In-Stent Restenosis. Journal of Clinical Medicine, 2024, 13, 2377.	3.8	34
41	Efficacy and Safety of Drugs in Residual Cardiovascular Risk: A Systematic Review of the Literature. International Journal of Cardiology Cardiovascular Risk and Prevention, 2024, 22, 200298.	2.7	2
42	Bio-Inspired One-Pot Synthesis of Luminescent Silver Nanoparticles and Its Significant Utility as a Fluorescence Nano Sensor for Analysis of Two Adjunctive COVID-19 Drugs. BMC Chemistry, 2024, 18, 1-21.	5.2	3
43	Long-Term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence. Clinical Therapeutics, 2025, 47, 511-518.	3.4	4
44	P2Y12 Inhibitor or Aspirin After Percutaneous Coronary Intervention: Individual Patient Data Meta-Analysis of Randomised Clinical Trials. BMJ, The, 2025, 389, e082561.	11.6	53
45	Antithrombotic Therapy in Complex Percutaneous Coronary Intervention. EuroIntervention, 2025, 21, e1051-e1068.	4.9	44
46	Secondary Prevention After Myocardial Infarction: Bridging Evidence to Practice. Canadian Cardiology Today, 2025, .	0.0	0
47	Practical Hospitalist Guide to Inpatient Cardiology. , 2025, .		0
48	Diretriz de Síndrome Coronariana Crônica – 2025. Arquivos Brasileiros De Cardiologia, 2025, 122, e20250619.	1.2	7
49	Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2025, 14, 8334.	3.8	15
50	The Role of Rivaroxaban in the Management of Coronary Artery Disease: An Overview of Five Landmark Clinical Trials. Naunyn-Schmiedeberg's Archives of Pharmacology, 2026, 399, 1-11.	4.7	0
51	Dual Pathway Inhibition: Redefining the Secondary Prevention COMPASS in Chronic Coronary Artery Disease. International Journal of Angiology, 2025, .	1.1	0
52	From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis. Current Atherosclerosis Reports, 2026, 28, 26.	7.3	7
53	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❁SAIMSARA. , 2026, .		0
54	Antithrombotic Strategies After Complex Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2026, 15, 5196.	3.8	0